艾莎和努维安生物公司正在寻求欧盟批准肺癌药物塔列特里尼布. Eisai and Nuvation Bio seek EU approval for lung cancer drug taletrectinib.

艾赛和努维安生物宣布,欧洲药物管理局已经批准了对塔莱特雷克提尼布的营销申请.这是一种已在美国,中国和日本获得批准的肺癌治疗方法. Eisai and Nuvation Bio announced that the European Medicines Agency has validated a marketing application for taletrectinib, a lung cancer treatment already approved in the U.S., China, and Japan. 该药物针对ROS1阳性非小细胞肺癌,该病例约占2%,公司希望在标准审查时间表后将其成为欧洲的护理标准. The drug targets ROS1-positive non-small cell lung cancer, which affects about 2% of cases, and the companies hope it will become a standard of care in Europe following a standard review timeline.